Document is current
Any future updates will be listed below
-
Authors
Fleischer, Michael
Coskun, Bayram
Stolte, Benjamin
Della-Marina, Adela
Kölbel, Heike
Lax, Hildegard
Nonnemacher, Michael
Kleinschnitz, Christoph
Schara-Schmidt, Ulrike
Hagenacker, Tim https://orcid.org/0000-0002-3631-3450
-
Funding
Funding for this research was provided by:
Sanofi Genzyme
- License Information
-
More Information
Article History
Received: 29 April 2022
Accepted: 19 July 2022
First Online: 5 September 2022
Declarations
:
: For this work, the authors did not perform any studies on humans or animals. The studies are subject to the stated ethical guidelines.
: All authors have given approval to the publication of the protocol paper.
: This publication was supported by Sanofi Genzyme/Sanofi-Aventis Deutschland GmbH. TH has received lecture and consulting fees from Biogen, Roche, Novartis Gene therapies, Sanofi-Genzyme, and Alexion. US has received speaking and consulting fees from Biogen, Roche, Novartis Gene therapies, Sanofi-Genzyme, and Alexion. HK has received lecture fees from Pfizer, Roche, Novartis, and Sanofi) and is on the Advisory Board (Avexis/Novartis). MF, BC, BS, ADM, HL, MN, CK have no conflicts of interest to declare.
